S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
NYSE:RDY

Dr. Reddy's Laboratories (RDY) Stock Price, News & Analysis

$71.14
+0.23 (+0.32%)
(As of 04/19/2024 ET)
Today's Range
$70.72
$71.30
50-Day Range
$70.92
$77.61
52-Week Range
$53.12
$77.72
Volume
116,991 shs
Average Volume
161,224 shs
Market Capitalization
$11.87 billion
P/E Ratio
18.77
Dividend Yield
0.58%
Price Target
$80.00

Dr. Reddy's Laboratories MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
12.5% Upside
$80.00 Price Target
Short Interest
Healthy
0.38% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
-0.06mentions of Dr. Reddy
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
4.04%
From $3.96 to $4.12 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.02 out of 5 stars

Medical Sector

553rd out of 907 stocks

Pharmaceutical Preparations Industry

252nd out of 424 stocks

RDY stock logo

About Dr. Reddy's Laboratories Stock (NYSE:RDY)

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

RDY Stock Price History

RDY Stock News Headlines

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
RDY Jun 2024 60.000 call
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Dr. Reddy’s Q3 & 9M FY24 Financial Results
Dr. Reddy's just downgraded at Jefferies, here's why
Dr. Reddy's (RDY) Q2 Earnings and Revenues Beat Estimates
Dr. Reddy’s Q2 FY24 Financial Results
Here's Why Doctor Reddy's (RDY) is a Strong Growth Stock
See More Headlines
Receive RDY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dr. Reddy's Laboratories and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
1/31/2024
Today
4/21/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Employees
25,863
Year Founded
1984

Price Target and Rating

Average Stock Price Target
$80.00
High Stock Price Target
$80.00
Low Stock Price Target
$80.00
Potential Upside/Downside
+12.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
4 Analysts

Profitability

Net Income
$548 million
Pretax Margin
25.04%

Debt

Sales & Book Value

Annual Sales
$2.99 billion
Cash Flow
$4.21 per share
Book Value
$16.87 per share

Miscellaneous

Free Float
163,540,000
Market Cap
$11.87 billion
Optionable
Optionable
Beta
0.58

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Gunupati Venkateswara Prasad B.E. (Age 64)
    Co-Chairman, MD & Member of Management Council
    Comp: $2.25M
  • Mr. Kallam Satish Reddy B.Tech. (Age 57)
    M.S., Chairman of the Board & Member of the Management Council
    Comp: $1.38M
  • Mr. Erez Israeli M.B.A. (Age 56)
    CEO & Member of the Management Council
  • Mr. Parag Agarwal (Age 57)
    CFO & Member of Management Council
  • Mr. Deepak Sapra M.B.A. (Age 49)
    CEO of API & Services & Member of Management Council
  • Mr. Venkata Ramana Motupalli M.B.A. (Age 55)
    CEO of Branded Markets - India & Emerging Countries and Member of Management Council
  • Ms. Archana Bhaskar B.Sc. (Age 57)
    M.B.A., EVP, Head of Corporate Communications, Chief Human Resources Officer & Member of Management Council
  • Mr. Sanjay Sharma B.Tech. (Age 56)
    Executive VP, Global Head of Global Manufacturing & Member of Management Council
  • Mr. Marc Kikuchi B.A. (Age 55)
    M.B.A., CEO of North America Generics & Member of Management Council
  • Mr. Patrick Aghanian B.A. (Age 59)
    M.B.A., CEO of European Generics & Member of Management Council

RDY Stock Analysis - Frequently Asked Questions

Should I buy or sell Dr. Reddy's Laboratories stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Dr. Reddy's Laboratories in the last year. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" RDY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RDY, but not buy additional shares or sell existing shares.
View RDY analyst ratings
or view top-rated stocks.

What is Dr. Reddy's Laboratories' stock price target for 2024?

4 analysts have issued twelve-month price targets for Dr. Reddy's Laboratories' stock. Their RDY share price targets range from $80.00 to $80.00. On average, they anticipate the company's share price to reach $80.00 in the next year. This suggests a possible upside of 12.5% from the stock's current price.
View analysts price targets for RDY
or view top-rated stocks among Wall Street analysts.

How have RDY shares performed in 2024?

Dr. Reddy's Laboratories' stock was trading at $69.58 at the beginning of the year. Since then, RDY stock has increased by 2.2% and is now trading at $71.14.
View the best growth stocks for 2024 here
.

When is Dr. Reddy's Laboratories' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our RDY earnings forecast
.

How were Dr. Reddy's Laboratories' earnings last quarter?

Dr. Reddy's Laboratories Limited (NYSE:RDY) released its earnings results on Wednesday, January, 31st. The company reported $0.99 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.88 by $0.11. The business earned $867 million during the quarter, compared to the consensus estimate of $827.81 million. Dr. Reddy's Laboratories had a trailing twelve-month return on equity of 20.97% and a net margin of 19.26%.

How often does Dr. Reddy's Laboratories pay dividends? What is the dividend yield for Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories declared an annual dividend on Tuesday, July 18th. Shareholders of record on Friday, January 1st will be given a dividend of $0.4877 per share on Friday, July 28th. This represents a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, July 28th. This is an increase from the stock's previous annual dividend of $0.33.
Read our dividend analysis for RDY
.

Is Dr. Reddy's Laboratories a good dividend stock?

Dr. Reddy's Laboratories (NYSE:RDY) pays an annual dividend of $0.41 per share and currently has a dividend yield of 0.58%. The company has been increasing its dividend for 4 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 10.82%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RDY will have a dividend payout ratio of 9.95% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for RDY.

What is G. V. Prasad's approval rating as Dr. Reddy's Laboratories' CEO?

528 employees have rated Dr. Reddy's Laboratories Chief Executive Officer G. V. Prasad on Glassdoor.com. G. V. Prasad has an approval rating of 96% among the company's employees. This puts G. V. Prasad in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Dr. Reddy's Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dr. Reddy's Laboratories investors own include Siemens Aktiengesellschaft (SIEGY), Tata Motors (TTM), Infosys (INFY), HDFC Bank (HDB), Alibaba Group (BABA), GSK (GSK), Merck & Co., Inc. (MRK), NVIDIA (NVDA) and Pfizer (PFE).

Who are Dr. Reddy's Laboratories' major shareholders?

Dr. Reddy's Laboratories' stock is owned by many different retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.07%), Lifestyle Asset Management Inc. (0.01%), Ballentine Partners LLC (0.01%), First Trust Direct Indexing L.P. (0.01%), DGS Capital Management LLC (0.01%) and Artemis Investment Management LLP (0.00%).

How do I buy shares of Dr. Reddy's Laboratories?

Shares of RDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:RDY) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners